Search results for "Adverse effect"

showing 10 items of 1065 documents

The Use of Hepatocytes to Investigate Drug Toxicity

2010

The liver is very active in metabolizing foreign compounds and the major target for toxicity caused by drugs. Hepatotoxicity may be the result of the drug itself or, more frequently, a result of the bioactivation process and the production of reactive metabolites. Prioritization of compounds based on human hepatotoxicity potential is currently a key unmet need in drug discovery, as it can become a major problem for several lead compounds in later stages of the drug discovery pipeline. Therefore, evaluation of potential hepatotoxicity represents a critical step in the development of new drugs. Cultured hepatocytes are increasingly used by the pharmaceutical industry for the screening of hepa…

Drugbusiness.industryDrug discoverymedia_common.quotation_subjectPharmacologymedicine.disease_causeToxic injuryToxicityMedicineAdverse effectbusinessCytotoxicityHomeostasisOxidative stressmedia_common
researchProduct

Naloxone in Treating Central Adverse Effects During Opioid Titration for Cancer Pain

2003

Drugbusiness.industrymedia_common.quotation_subject(+)-NaloxoneAnesthesiology and Pain MedicineOpioidAnesthesiamedicineNeurology (clinical)Cancer painMorphine poisoningAdverse effectbusinessGeneral Nursingmedicine.drugmedia_commonJournal of Pain and Symptom Management
researchProduct

Use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics.

2016

Age represents an exclusion criterion in randomized clinical trials designed to test the efficacy and safety of inhaled drugs in asthma. As a consequence, data on efficacy and safety of inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA) combinations in elderly asthmatics are scanty. Older age is associated with an increased proportion of comorbid conditions; in addition, all organ functions undergo a process of senescence, thus reducing their ability to metabolize the agents. Overall, these age-associated conditions may variably, and often unpredictably, affect the metabolism and excretion of respiratory drugs. However, pharmacological treatment of asthma does not follow specifi…

Druglong-acting β2 agonistmedicine.medical_specialtyasthma treatmentmedia_common.quotation_subjectPopulationReviewSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialPharmacokineticsInhaled corticosteroidlawmedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticseducationAdverse effectIntensive care medicineAsthmamedia_commoneducation.field_of_studyChemical Health and SafetyInhalationbusiness.industryaginglung functionGeneral Medicinemedicine.diseasecomorbidity030228 respiratory systemAnesthesiaPharmacodynamicslong-acting β2 agonistsinhaled corticosteroidsbusinessSafety ResearchTherapeutics and clinical risk management
researchProduct

Recent progress in the pharmacotherapy of cancer pain.

2001

Cancer pain can be relatively well managed with primary therapies, according to the WHO ladder. However, different conditions may limit the response to the analgesic drug used, which are mainly oploids. Specifically, adverse effects may prevail against the analgesic activity in the clinical setting. New pharmacological strategies may enable a more satisfactory response to be obtained, in terms of balance between analgesia and adverse effects. The change of route of administration or the use of alternative opioids is a first-line option. The use of adjuvant drugs may also improve analgesia with different mechanisms. Recent studies have demonstrated the value of these alternative approaches. …

Drugmedicine.medical_specialtyAnalgesicsbusiness.industrymedicine.medical_treatmentmedia_common.quotation_subjectAnalgesicPainPain ladderRoute of administrationPharmacotherapyOncologyAnesthesiaNeoplasmsmedicineHumansPharmacology (medical)Drug InteractionsIntensive care medicineCancer painAdverse effectbusinessAdjuvantmedia_commonExpert review of anticancer therapy
researchProduct

Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm…

2020

Background and objectives: Current psoriasis guidelines do not usually include recommendations about first line classical or biologic treatment. The objectives of this study were: to describe shifts in the prescription of the first biological treatment, and to compare treatment withdrawal and rates of adverse events over ten years. Material and methods: Biobadaderm registry was analyzed to describe: first biological prescription in bio-naive patients, adverse events rate and reasons for drug withdrawal comparing three periods of time (2008-2010, 2011-2014, 2015-2018). Results: Anti-TNF drugs were the most prescribed biological drug from 2008 to 2010. Ustekinumab has become the most prescrib…

Drugmedicine.medical_specialtyHistologyBiologicmedia_common.quotation_subjectDiscontinuationDermatologyBiologic treatmentPathology and Forensic Medicine030207 dermatology & venereal diseases03 medical and health sciencesDrug withdrawal0302 clinical medicinePsoriasisUstekinumabTrendmedicinePsoriasisMedical prescriptionIntensive care medicineAdverse effectmedia_commonbusiness.industryBiobadadermmedicine.diseaseDiscontinuationTreatment030220 oncology & carcinogenesisbusinessmedicine.drug
researchProduct

Antiepileptic drug use in nursing homes

2007

Contrary to former views, the incidence rate of epilepsy after the age of 65 years is higher than in childhood and adolescence, and epileptic seizures are one of the most common neurological problems in the elderly. Given that the incidence of epilepsy increases with advancing age and is not accompanied by an increase in mortality and given that elderly people now live longer, the prevalence of epilepsy is increasing with older age. Antiepileptic drugs (AEDs) are the primary treatment for epilepsy, although they are prescribed for other conditions too. Among nursing home residents the prevalence of seizures or epilepsy is between 5 and 8%, while AEDs are taken by approximately 5–10%. It is…

Drugmedicine.medical_specialtyPediatricsbusiness.industrymedia_common.quotation_subjectIncidence (epidemiology)Antiepileptic drugGeneral Medicinemedicine.diseaseEpilepsymedicineElderly peopleGeriatrics and GerontologyMedical prescriptionPsychiatryAdverse effectbusinessNursing homesmedia_commonAging Health
researchProduct

Are the Adverse Drug Reactions of Amoxycillin and Amoxycillin-Clavulanic Acid Similar?

1996

UNLABELLED In an attempt to assess the relative toxicity of amoxycillin and amoxycillin-clavulanic acid, we compared the adverse drug reactions reports collected using the spontaneous reporting system of a Regional Drug Surveillance Centre of Spain for both drugs between November 1986 and December 1992. During the 7-year period 1986-92, the 247 reports of amoxycillin-clavulanic acid represent twice the number of reports of amoxycillin alone, and the number of reports related with sales received concerning the association were higher than those concerning amoxycillin alone. The adverse effects classified as severe were quantitatively and qualitatively similar for both drugs and gastrointesti…

Drugmedicine.medical_specialtyRelative toxicityEpidemiologybusiness.industrymedia_common.quotation_subjectAmoxycillin-Clavulanic AcidPharmacologyReporting rateInternal medicineSpontaneous reportingpolycyclic compoundsmedicinePharmacology (medical)Drug reactionAdverse effectbusinessmedia_commonPharmacoepidemiology and Drug Safety
researchProduct

New drugs for pain management in advanced cancer patients.

2017

Advanced cancer patients represent a frail population, often requiring aggressive pain management, particularly in the late stage of disease, when untreated pain is one the most important causes of suffering. Areas covered: In the last decade, a series of new analgesics have been introduced in the market to offer additional options amongst existent drugs. The characteristics of these drugs, their efficacy and tolerability are examined on the basis of existent studies. Expert opinion: Although new analgesic preparations have been developed in recent years, no specific drug has provided a better analgesic performance in comparison with others. Some technologies have been developed to increase…

Drugmedicine.medical_specialtymedia_common.quotation_subjectAnalgesicPopulationPainDiseasePain ladder03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansPharmacology (medical)Adverse effectIntensive care medicineeducationmedia_commonPain MeasurementPharmacologyeducation.field_of_studyAnalgesicsbusiness.industryBreakthrough PainGeneral MedicineAnalgesics OpioidTolerability030220 oncology & carcinogenesisAnesthesiaCancer painbusiness030217 neurology & neurosurgeryExpert opinion on pharmacotherapy
researchProduct

Weight-based dosing: Which impact on efficacy and safety of therapy?

2004

Abstract Pegylated interferons (PEG-IFNs) in combination with ribavirin represent the most recent advance in the treatment of patients withchronic hepatitis C (CHC): two large clinical trials have shown a superior efficacy in clearing HCV in almost 60% of treated naive patients. Responses to antiviral treatment of CHC vary according to both viral and host factors. Managing patients with CHC infection requires individualised treatment strategies to optimise outcomes. Several landmark publications on PEG-IFNs have reported that weight is a significant predictive factor for SVR in the treatment of CHC with fixed-dose drug administration. With fixed-dose treatment, there is a direct correlation…

Drugmedicine.medical_specialtymedia_common.quotation_subjectChronic hepatitis Cchemistry.chemical_compoundPegylated interferonInternal medicinemedicineDosingAdverse effectmedia_commonHepatologybusiness.industryWeight-based dosingRibavirinGastroenterologyvirus diseasesHepatitis Cmedicine.diseaseSurgeryClinical trialchemistrybusinessWeight based dosingPegylated interferonmedicine.drugDigestive and Liver Disease
researchProduct

Therapeutic drug monitoring for antidepressant drug treatment.

2012

The aim of antidepressant drug treatment is to produce remission without causing adverse effects during the acute phase of the illness and to prevent relapses or recurrences during continuation or maintenance therapy. To achieve these goals, drug choice and dosage must be optimized for each patient individually. Therapeutic drug monitoring (TDM), which is based on the assumption that clinical effects correlate better with blood levels than doses, can be helpful. When using tricyclic antidepressant drugs TDM enhances safety and efficacy. For newer antidepressant drugs, however, it is a matter of debate to which extend TDM can have beneficial effects. For many antidepressants there exist care…

Drugmedicine.medical_specialtymedia_common.quotation_subjectCost-Benefit AnalysisPharmacologyDrug CostsDrug treatmentPharmacokineticsMaintenance therapyDrug DiscoveryPharmacovigilancemedicineSecondary PreventionHumansAdverse effectIntensive care medicinemedia_commonPharmacologymedicine.diagnostic_testbusiness.industryDepressionRemission InductionAntidepressive AgentsTreatment OutcomeTherapeutic drug monitoringAntidepressantDrug MonitoringbusinessCurrent pharmaceutical design
researchProduct